{"transactions":[{"id":3527104,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-08T20:33:27.000Z","date":"2026-09-03","kind":"purchase","planned":false,"acquired":true,"shares":89200,"price":11.5588,"value":1031044.96,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $11.17 to $11.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by Peter Svennilson."}],"balance_after":89200,"source":{"system":"sec-edgar","filing":"0001193125-26-385268","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1932874/000119312526385268/ownership.xml","form_type":"4"}},{"id":879653,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T16:23:09.000Z","date":"2026-02-25","kind":"sale","planned":false,"acquired":false,"shares":1862545,"price":0.5624,"value":1047495.308,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group III-A, LP (\"TCG III-A LP\"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-076814","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526076814/ownership.xml","form_type":"4"}},{"id":879652,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T16:23:09.000Z","date":"2026-02-25","kind":"sale","planned":false,"acquired":false,"shares":1649281,"price":0.5624,"value":927555.6344,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group III, LP (\"TCG III LP\"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the \"Managing Partners\"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-076814","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526076814/ownership.xml","form_type":"4"}},{"id":879651,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T16:23:09.000Z","date":"2026-02-24","kind":"sale","planned":false,"acquired":false,"shares":349212,"price":0.6153,"value":214870.1436,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group III-A, LP (\"TCG III-A LP\"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares."}],"balance_after":1862545,"source":{"system":"sec-edgar","filing":"0001193125-26-076814","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526076814/ownership.xml","form_type":"4"}},{"id":879650,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T16:23:09.000Z","date":"2026-02-24","kind":"sale","planned":false,"acquired":false,"shares":309228,"price":0.6153,"value":190267.9884,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group III, LP (\"TCG III LP\"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the \"Managing Partners\"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares."}],"balance_after":1649281,"source":{"system":"sec-edgar","filing":"0001193125-26-076814","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526076814/ownership.xml","form_type":"4"}},{"id":884848,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-24T16:13:06.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":162291,"price":0.5972,"value":96920.1852,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.573 to $0.6225, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group III-A, LP (\"TCG III-A LP\"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares."}],"balance_after":2211757,"source":{"system":"sec-edgar","filing":"0001193125-26-067007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526067007/ownership.xml","form_type":"4"}},{"id":884847,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-24T16:13:06.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":143709,"price":0.5972,"value":85823.0148,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.573 to $0.6225, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group III, LP (\"TCG III LP\"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the \"Managing Partners\"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares."}],"balance_after":1958509,"source":{"system":"sec-edgar","filing":"0001193125-26-067007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526067007/ownership.xml","form_type":"4"}},{"id":884846,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-24T16:13:06.000Z","date":"2026-02-20","kind":"sale","planned":false,"acquired":false,"shares":277769,"price":0.6149,"value":170800.1581,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.60 to $0.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group III-A, LP (\"TCG III-A LP\"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares."}],"balance_after":2374048,"source":{"system":"sec-edgar","filing":"0001193125-26-067007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526067007/ownership.xml","form_type":"4"}},{"id":884845,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-24T16:13:06.000Z","date":"2026-02-20","kind":"sale","planned":false,"acquired":false,"shares":245965,"price":0.6149,"value":151243.8785,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.60 to $0.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group III, LP (\"TCG III LP\"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the \"Managing Partners\"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares."}],"balance_after":2102218,"source":{"system":"sec-edgar","filing":"0001193125-26-067007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526067007/ownership.xml","form_type":"4"}},{"id":907577,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-12T17:19:03.000Z","date":"2026-02-11","kind":"sale","planned":false,"acquired":false,"shares":2151458,"price":0.6808,"value":1464712.6064,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.65 to $0.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group III-A, LP (\"TCG III-A LP\"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares."}],"balance_after":2651817,"source":{"system":"sec-edgar","filing":"0001193125-26-049028","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526049028/ownership.xml","form_type":"4"}},{"id":907576,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-12T17:19:03.000Z","date":"2026-02-11","kind":"sale","planned":false,"acquired":false,"shares":1905115,"price":0.6808,"value":1297002.292,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.65 to $0.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group III, LP (\"TCG III LP\"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the \"Managing Partners\"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares."}],"balance_after":2348183,"source":{"system":"sec-edgar","filing":"0001193125-26-049028","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526049028/ownership.xml","form_type":"4"}},{"id":907575,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-12T17:19:03.000Z","date":"2026-02-10","kind":"sale","planned":false,"acquired":false,"shares":182295,"price":0.8161,"value":148770.9495,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group III-A, LP (\"TCG III-A LP\"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares."}],"balance_after":4803275,"source":{"system":"sec-edgar","filing":"0001193125-26-049028","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526049028/ownership.xml","form_type":"4"}},{"id":907574,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-12T17:19:03.000Z","date":"2026-02-10","kind":"sale","planned":false,"acquired":false,"shares":161422,"price":0.8161,"value":131736.4942,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group III, LP (\"TCG III LP\"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the \"Managing Partners\"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares."}],"balance_after":4253298,"source":{"system":"sec-edgar","filing":"0001193125-26-049028","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526049028/ownership.xml","form_type":"4"}},{"id":914582,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":false,"shares":5133076,"ownership":{"direct":false,"nature":"By The Column Group Opportunity III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":688283},"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":914581,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":false,"shares":28229,"ownership":{"direct":false,"nature":"By The Column Group IV-A, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3785},"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":914580,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":false,"shares":827278,"ownership":{"direct":false,"nature":"By The Column Group IV, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":110928},"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":914579,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":false,"shares":357216,"ownership":{"direct":false,"nature":"By The Column Group IV-A, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":47898},"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":914578,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":false,"shares":10467526,"ownership":{"direct":false,"nature":"By The Column Group IV, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1403568},"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":914577,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":false,"shares":330000,"ownership":{"direct":false,"nature":"By The Column Group IV-A, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":44249},"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":914576,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":false,"shares":9670000,"ownership":{"direct":false,"nature":"By The Column Group IV, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1296629},"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":914575,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"purchase","planned":false,"acquired":true,"shares":630881,"price":18,"value":11355858.0,"ownership":{"direct":false,"nature":"By The Column Group Opportunity III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":1319164,"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":914574,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"purchase","planned":false,"acquired":true,"shares":49556,"price":18,"value":892008.0,"ownership":{"direct":false,"nature":"By The Column Group IV-A, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":148840,"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":914573,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"purchase","planned":false,"acquired":true,"shares":1437323,"price":18,"value":25871814.0,"ownership":{"direct":false,"nature":"By The Column Group IV, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":4312139,"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":914572,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":true,"shares":688283,"ownership":{"direct":false,"nature":"By The Column Group Opportunity III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":688283,"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":914571,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":true,"shares":3785,"ownership":{"direct":false,"nature":"By The Column Group IV-A, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":99284,"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":914570,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":true,"shares":47898,"ownership":{"direct":false,"nature":"By The Column Group IV-A, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":95499,"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":914569,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":true,"shares":44249,"ownership":{"direct":false,"nature":"By The Column Group IV-A, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":47601,"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":914568,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":true,"shares":110928,"ownership":{"direct":false,"nature":"By The Column Group IV, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":2874816,"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":914567,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":true,"shares":1403568,"ownership":{"direct":false,"nature":"By The Column Group IV, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":2763888,"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":914566,"issuer":{"id":5380,"kind":"organization","name":"Eikon Therapeutics, Inc.","symbol":"EIKN"},"owners":[{"id":67267,"kind":"organization","name":"Column Group IV GP, LP","position":1,"cik":"0001796356","reported_name":"Column Group IV GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67268,"kind":"organization","name":"Column Group IV-A, LP","position":2,"cik":"0001796353","reported_name":"Column Group IV-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67269,"kind":"organization","name":"Column Group IV, LP","position":3,"cik":"0001796354","reported_name":"Column Group IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":8,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T02:19:00.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":true,"shares":1296629,"ownership":{"direct":false,"nature":"By The Column Group IV, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein."}],"balance_after":1360320,"source":{"system":"sec-edgar","filing":"0001193125-26-043320","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526043320/ownership.xml","form_type":"4"}},{"id":935386,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":7,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-20T19:35:33.000Z","date":"2026-01-20","kind":"purchase","planned":false,"acquired":true,"shares":9568,"price":19.5999,"value":187531.8432,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group III-A, LP (\"TCG III-A LP\"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1016658,"source":{"system":"sec-edgar","filing":"0001193125-26-016991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526016991/ownership.xml","form_type":"4"}},{"id":935385,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":7,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-20T19:35:33.000Z","date":"2026-01-20","kind":"purchase","planned":false,"acquired":true,"shares":8484,"price":19.5999,"value":166285.5516,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by The Column Group III, LP (\"TCG III LP\"). The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":900292,"source":{"system":"sec-edgar","filing":"0001193125-26-016991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526016991/ownership.xml","form_type":"4"}},{"id":935384,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":7,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-20T19:35:33.000Z","date":"2026-01-16","kind":"purchase","planned":false,"acquired":true,"shares":1358,"price":20,"value":27160.0,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group III-A, LP (\"TCG III-A LP\"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1007090,"source":{"system":"sec-edgar","filing":"0001193125-26-016991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526016991/ownership.xml","form_type":"4"}},{"id":935383,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":7,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-20T19:35:33.000Z","date":"2026-01-16","kind":"purchase","planned":false,"acquired":true,"shares":1204,"price":20,"value":24080.0,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by The Column Group III, LP (\"TCG III LP\"). The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":891808,"source":{"system":"sec-edgar","filing":"0001193125-26-016991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526016991/ownership.xml","form_type":"4"}},{"id":935382,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":7,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-20T19:35:33.000Z","date":"2026-01-15","kind":"purchase","planned":false,"acquired":true,"shares":6303,"price":19.889,"value":125360.367,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group III-A, LP (\"TCG III-A LP\"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1005732,"source":{"system":"sec-edgar","filing":"0001193125-26-016991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526016991/ownership.xml","form_type":"4"}},{"id":935381,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":7,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-20T19:35:33.000Z","date":"2026-01-15","kind":"purchase","planned":false,"acquired":true,"shares":5590,"price":19.889,"value":111179.51,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by The Column Group III, LP (\"TCG III LP\"). The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":890604,"source":{"system":"sec-edgar","filing":"0001193125-26-016991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526016991/ownership.xml","form_type":"4"}},{"id":938496,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":7,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-15T16:10:41.000Z","date":"2026-01-14","kind":"purchase","planned":false,"acquired":true,"shares":2927,"price":19.9883,"value":58505.7541,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group III-A, LP (\"TCG III-A LP\"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":999429,"source":{"system":"sec-edgar","filing":"0001193125-26-014100","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526014100/ownership.xml","form_type":"4"}},{"id":938495,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":7,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-15T16:10:41.000Z","date":"2026-01-14","kind":"purchase","planned":false,"acquired":true,"shares":2596,"price":19.9883,"value":51889.6268,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by The Column Group III, LP (\"TCG III LP\"). The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":885014,"source":{"system":"sec-edgar","filing":"0001193125-26-014100","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526014100/ownership.xml","form_type":"4"}},{"id":938494,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":7,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-15T16:10:41.000Z","date":"2026-01-13","kind":"purchase","planned":false,"acquired":true,"shares":6609,"price":19.8041,"value":130885.2969,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group III-A, LP (\"TCG III-A LP\"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":996502,"source":{"system":"sec-edgar","filing":"0001193125-26-014100","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526014100/ownership.xml","form_type":"4"}},{"id":938493,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":7,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-15T16:10:41.000Z","date":"2026-01-13","kind":"purchase","planned":false,"acquired":true,"shares":5861,"price":19.8041,"value":116071.8301,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by The Column Group III, LP (\"TCG III LP\"). The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":882418,"source":{"system":"sec-edgar","filing":"0001193125-26-014100","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526014100/ownership.xml","form_type":"4"}},{"id":943223,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":7,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-08T17:23:33.000Z","date":"2026-01-06","kind":"purchase","planned":false,"acquired":true,"shares":8003,"price":19.8872,"value":159157.2616,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group III-A, LP (\"TCG III-A LP\"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":989893,"source":{"system":"sec-edgar","filing":"0001193125-26-007857","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526007857/ownership.xml","form_type":"4"}},{"id":943222,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":7,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-08T17:23:33.000Z","date":"2026-01-06","kind":"purchase","planned":false,"acquired":true,"shares":7097,"price":19.8872,"value":141139.4584,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by The Column Group III, LP (\"TCG III LP\"). The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":876557,"source":{"system":"sec-edgar","filing":"0001193125-26-007857","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312526007857/ownership.xml","form_type":"4"}},{"id":977611,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-08T17:04:34.000Z","date":"2025-12-05","kind":"purchase","planned":false,"acquired":true,"shares":16381,"price":19.5409,"value":320099.4829,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group III-A, LP (\"TCG III-A LP\"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":981890,"source":{"system":"sec-edgar","filing":"0001193125-25-311384","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312525311384/ownership.xml","form_type":"4"}},{"id":977610,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-08T17:04:34.000Z","date":"2025-12-04","kind":"purchase","planned":false,"acquired":true,"shares":2791,"price":17.347,"value":48415.477,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group III-A, LP (\"TCG III-A LP\"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":965509,"source":{"system":"sec-edgar","filing":"0001193125-25-311384","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312525311384/ownership.xml","form_type":"4"}},{"id":977609,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-08T17:04:34.000Z","date":"2025-12-05","kind":"purchase","planned":false,"acquired":true,"shares":14503,"price":19.5409,"value":283401.6727,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by The Column Group III, LP (\"TCG III LP\"). The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":869460,"source":{"system":"sec-edgar","filing":"0001193125-25-311384","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312525311384/ownership.xml","form_type":"4"}},{"id":977608,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-08T17:04:34.000Z","date":"2025-12-04","kind":"purchase","planned":false,"acquired":true,"shares":2475,"price":17.347,"value":42933.825,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by The Column Group III, LP (\"TCG III LP\"). The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":854957,"source":{"system":"sec-edgar","filing":"0001193125-25-311384","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312525311384/ownership.xml","form_type":"4"}},{"id":997755,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-17T19:15:37.000Z","date":"2025-11-13","kind":"purchase","planned":false,"acquired":true,"shares":167307,"price":12.65,"value":2116433.55,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":962718,"source":{"system":"sec-edgar","filing":"0001193125-25-284943","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312525284943/ownership.xml","form_type":"4"}},{"id":997754,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-17T19:15:37.000Z","date":"2025-11-13","kind":"purchase","planned":false,"acquired":true,"shares":148150,"price":12.65,"value":1874097.5,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by TCG III LP. The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":852482,"source":{"system":"sec-edgar","filing":"0001193125-25-284943","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000119312525284943/ownership.xml","form_type":"4"}},{"id":1188850,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Second Tranche Units (Right to Buy)","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":517241,"ownership":{"direct":false,"nature":"By The Column Group Opportunity II, LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F11","text":"Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the \"Second Closing\"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the \"Second Closing Milestone\"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the \"Termination Notice\")."},{"field":"security","element":"securityTitle","label":"F12","text":"(Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the \"Second Closing\"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the \"Second Closing Milestone\"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the \"Termination Notice\")."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"(Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the \"Second Closing\"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the \"Second Closing Milestone\"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the \"Termination Notice\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"(Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the \"Second Closing\"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the \"Second Closing Milestone\"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the \"Termination Notice\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"(Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F15","text":"Consists of (a) 517,241 shares of the Issuer's Common Stock and (b) 258,620 Series E Warrants to purchase shares of the Issuer's Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Members\"). TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":517241,"derivative":{"exercise_price":11.6,"underlying":"Common Stock","underlying_shares":775861},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188849,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Second Tranche Units (Right to Buy)","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":548653,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F11","text":"Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the \"Second Closing\"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the \"Second Closing Milestone\"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the \"Termination Notice\")."},{"field":"security","element":"securityTitle","label":"F12","text":"(Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the \"Second Closing\"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the \"Second Closing Milestone\"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the \"Termination Notice\")."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"(Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the \"Second Closing\"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the \"Second Closing Milestone\"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the \"Termination Notice\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"(Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the \"Second Closing\"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the \"Second Closing Milestone\"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the \"Termination Notice\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"(Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F14","text":"Consists of (a) 548,653 shares of the Issuer's Common Stock and (b) 274,327 Series E Warrants to purchase shares of the Issuer's Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":548653,"derivative":{"exercise_price":11.6,"underlying":"Common Stock","underlying_shares":822980},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188848,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Second Tranche Units (Right to Buy)","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":485830,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F11","text":"Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the \"Second Closing\"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the \"Second Closing Milestone\"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the \"Termination Notice\")."},{"field":"security","element":"securityTitle","label":"F12","text":"(Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the \"Second Closing\"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the \"Second Closing Milestone\"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the \"Termination Notice\")."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"(Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the \"Second Closing\"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the \"Second Closing Milestone\"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the \"Termination Notice\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"(Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the \"Second Closing\"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the \"Second Closing Milestone\"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the \"Termination Notice\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"(Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F13","text":"Consists of (a) 485,830 shares of the Issuer's Common Stock and (b) 242,915 Series E Warrants to purchase shares of the Issuer's Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by TCG III LP. The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":485830,"derivative":{"exercise_price":11.6,"underlying":"Common Stock","underlying_shares":728745},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188847,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Common Warrants","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":172414,"ownership":{"direct":false,"nature":"By The Column Group Opportunity II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP (\"TCG III LP\"), The Column Group III-A, LP (\"TCG III-A LP\") and The Column Group Opportunity III, LP (\"TCG Opportunity III LP\") purchased in the Issuer's private placement on March 24, 2025 (the \"2025 Private Placement\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Members\"). TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":172414,"derivative":{"exercise_price":11.54,"underlying":"Common Stock","underlying_shares":172414},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188846,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Common Warrants","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":182884,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP (\"TCG III LP\"), The Column Group III-A, LP (\"TCG III-A LP\") and The Column Group Opportunity III, LP (\"TCG Opportunity III LP\") purchased in the Issuer's private placement on March 24, 2025 (the \"2025 Private Placement\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":182884,"derivative":{"exercise_price":11.54,"underlying":"Common Stock","underlying_shares":182884},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188845,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Common Warrants","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":161943,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP (\"TCG III LP\"), The Column Group III-A, LP (\"TCG III-A LP\") and The Column Group Opportunity III, LP (\"TCG Opportunity III LP\") purchased in the Issuer's private placement on March 24, 2025 (the \"2025 Private Placement\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by TCG III LP. The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":161943,"derivative":{"exercise_price":11.54,"underlying":"Common Stock","underlying_shares":161943},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188844,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Common Warrants","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"other","planned":false,"acquired":false,"shares":397773,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":16,"underlying":"Common Stock","underlying_shares":397773},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188843,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Common Warrants","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"other","planned":false,"acquired":false,"shares":352225,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by TCG III LP. The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":16,"underlying":"Common Stock","underlying_shares":352225},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188842,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Common Warrants","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"other","planned":false,"acquired":false,"shares":397773,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":16,"underlying":"Common Stock","underlying_shares":397773},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188841,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Common Warrants","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"other","planned":false,"acquired":false,"shares":352225,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by TCG III LP. The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":16,"underlying":"Common Stock","underlying_shares":352225},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188840,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Common Warrants","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":111656,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"kind","element":"transactionCoding","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":111656,"derivative":{"exercise_price":11.54,"underlying":"Common Stock","underlying_shares":111656},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188839,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Common Warrants","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"other","planned":false,"acquired":false,"shares":111656,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"kind","element":"transactionCoding","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":14.25,"underlying":"Common Stock","underlying_shares":111656},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188838,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Common Warrants","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":98870,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"kind","element":"transactionCoding","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by TCG III LP. The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":98870,"derivative":{"exercise_price":11.54,"underlying":"Common Stock","underlying_shares":98870},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188837,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Common Warrants","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"other","planned":false,"acquired":false,"shares":98870,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"kind","element":"transactionCoding","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024.  The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement.  These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7)  and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by TCG III LP. The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":14.25,"underlying":"Common Stock","underlying_shares":98870},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188836,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Warrants","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":102651,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":102651,"derivative":{"exercise_price":11.54,"underlying":"Common Stock","underlying_shares":102651},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188835,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Warrants","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"other","planned":false,"acquired":false,"shares":102651,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":15.5,"underlying":"Common Stock","underlying_shares":102651},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188834,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Warrants","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":90897,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by TCG III LP. The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":90897,"derivative":{"exercise_price":11.54,"underlying":"Common Stock","underlying_shares":90897},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188833,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Common Warrants","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"other","planned":false,"acquired":false,"shares":90897,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by TCG III LP. The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":15.5,"underlying":"Common Stock","underlying_shares":90897},"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188832,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":344827,"price":11.6,"value":3999993.2,"ownership":{"direct":false,"nature":"By The Column Group Opportunity III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP (\"TCG III LP\"), The Column Group III-A, LP (\"TCG III-A LP\") and The Column Group Opportunity III, LP (\"TCG Opportunity III LP\") purchased in the Issuer's private placement on March 24, 2025 (the \"2025 Private Placement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Members\"). TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":344827,"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188831,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":365769,"price":11.6,"value":4242920.4,"ownership":{"direct":false,"nature":"By The Column Group III-A, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP (\"TCG III LP\"), The Column Group III-A, LP (\"TCG III-A LP\") and The Column Group Opportunity III, LP (\"TCG Opportunity III LP\") purchased in the Issuer's private placement on March 24, 2025 (the \"2025 Private Placement\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The amount beneficially owned by the Reporting Persons, has been updated to correct an administrative error in previously reported Form 4s."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":795411,"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1188830,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":2,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":3,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-28T20:57:08.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":323886,"price":11.6,"value":3757077.6,"ownership":{"direct":false,"nature":"By The Column Group III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP (\"TCG III LP\"), The Column Group III-A, LP (\"TCG III-A LP\") and The Column Group Opportunity III, LP (\"TCG Opportunity III LP\") purchased in the Issuer's private placement on March 24, 2025 (the \"2025 Private Placement\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The amount beneficially owned by the Reporting Persons, has been updated to correct an administrative error in previously reported Form 4s."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by TCG III LP. The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the \"Managing Partners\"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":704332,"source":{"system":"sec-edgar","filing":"0000950170-25-047104","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025047104/ownership.xml","form_type":"4"}},{"id":1217404,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant (right to buy)","published_at":"2025-03-07T19:14:40.000Z","date":"2025-03-05","kind":"purchase","planned":false,"acquired":true,"shares":17857142,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an underwritten public offering, The Column Group Opportunity III, LP (\"TCG Opportunity III LP\") purchased units (the \"Units\") at a price per Unit of $0.70 per Unit. Each Unit consists of (a) one share of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\", and such shares, the \"Shares\"), (b) one Series A warrant to purchase one share of Common Stock at an exercise price of $0.80 per share which will expire five years from the date of issuance (a \"Series A Warrant\") and (c) one half of a Series B warrant to purchase a share of Common Stock at an exercise price of $0.70 per share that will expire on June 30, 2026 (a \"Series B Warrant\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each Series B Warrant is immediately exercisable (subject to certain beneficial ownership limitations)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the Issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":17857142,"derivative":{"exercise_price":0.7,"expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":17857142},"source":{"system":"sec-edgar","filing":"0000950170-25-035789","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025035789/ownership.xml","form_type":"4"}},{"id":1217403,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant (right to buy)","published_at":"2025-03-07T19:14:40.000Z","date":"2025-03-05","kind":"purchase","planned":false,"acquired":true,"shares":35714284,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an underwritten public offering, The Column Group Opportunity III, LP (\"TCG Opportunity III LP\") purchased units (the \"Units\") at a price per Unit of $0.70 per Unit. Each Unit consists of (a) one share of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\", and such shares, the \"Shares\"), (b) one Series A warrant to purchase one share of Common Stock at an exercise price of $0.80 per share which will expire five years from the date of issuance (a \"Series A Warrant\") and (c) one half of a Series B warrant to purchase a share of Common Stock at an exercise price of $0.70 per share that will expire on June 30, 2026 (a \"Series B Warrant\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each Series A Warrant is immediately exercisable (subject to certain beneficial ownership limitations)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the Issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":35714284,"derivative":{"exercise_price":0.8,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":35714284},"source":{"system":"sec-edgar","filing":"0000950170-25-035789","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025035789/ownership.xml","form_type":"4"}},{"id":1217402,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-07T19:14:40.000Z","date":"2025-03-05","kind":"purchase","planned":false,"acquired":true,"shares":35714284,"price":0.7,"value":24999998.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an underwritten public offering, The Column Group Opportunity III, LP (\"TCG Opportunity III LP\") purchased units (the \"Units\") at a price per Unit of $0.70 per Unit. Each Unit consists of (a) one share of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\", and such shares, the \"Shares\"), (b) one Series A warrant to purchase one share of Common Stock at an exercise price of $0.80 per share which will expire five years from the date of issuance (a \"Series A Warrant\") and (c) one half of a Series B warrant to purchase a share of Common Stock at an exercise price of $0.70 per share that will expire on June 30, 2026 (a \"Series B Warrant\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the Issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":49313559,"source":{"system":"sec-edgar","filing":"0000950170-25-035789","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017025035789/ownership.xml","form_type":"4"}},{"id":1545444,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":1,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:05:48.000Z","date":"2024-04-05","kind":"other","planned":false,"acquired":true,"shares":1000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0000950142-24-001002","document":"eh240467037_4-ngm3.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095014224001002/eh240467037_4-ngm3.xml","form_type":"4"}},{"id":1545443,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":1,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:05:48.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"The securities were directly held by Peter Svennilson."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-001002","document":"eh240467037_4-ngm3.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095014224001002/eh240467037_4-ngm3.xml","form_type":"4"}},{"id":1545442,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":1,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:05:48.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The securities were owned solely by Tim Kutzkey."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-001002","document":"eh240467037_4-ngm3.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095014224001002/eh240467037_4-ngm3.xml","form_type":"4"}},{"id":1545441,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":1,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:05:48.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The securities were directly held by The Column Group Management LP (\"TCGM LP\"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-001002","document":"eh240467037_4-ngm3.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095014224001002/eh240467037_4-ngm3.xml","form_type":"4"}},{"id":1545440,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":1,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:05:48.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-001002","document":"eh240467037_4-ngm3.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095014224001002/eh240467037_4-ngm3.xml","form_type":"4"}},{"id":1545439,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":1,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:05:48.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1298908,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"The securities were directly held by Ponoi Capital II, LP (\"Ponoi II LP\"). Ponoi II Management, LLC (\"Ponoi II LLC\") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-001002","document":"eh240467037_4-ngm3.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095014224001002/eh240467037_4-ngm3.xml","form_type":"4"}},{"id":1545438,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":1,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:05:48.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1298908,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The securities were directly held by Ponoi Capital, LP (\"Ponoi LP\"). Ponoi Management, LLC (\"Ponoi LLC\") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-001002","document":"eh240467037_4-ngm3.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095014224001002/eh240467037_4-ngm3.xml","form_type":"4"}},{"id":1545437,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":1,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:05:48.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2265758,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities were directly held by The Column Group II, LP (\"TCG II LP\"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-001002","document":"eh240467037_4-ngm3.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095014224001002/eh240467037_4-ngm3.xml","form_type":"4"}},{"id":1545436,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":1,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:05:48.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":968990,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities were directly held by The Column Group III-A, LP (\"TCG III-A LP\"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-001002","document":"eh240467037_4-ngm3.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095014224001002/eh240467037_4-ngm3.xml","form_type":"4"}},{"id":1545435,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":1,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:05:48.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":858035,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The securities were directly held by The Column Group III, LP (\"TCG III LP\"). The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-001002","document":"eh240467037_4-ngm3.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095014224001002/eh240467037_4-ngm3.xml","form_type":"4"}},{"id":1545434,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":1,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:05:48.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11103333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"The securities were directly held by The Column Group, LP (\"TCG LP\").The Column Group GP, LP (\"TCG GP\") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the \"TCG Managing Partners\"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-001002","document":"eh240467037_4-ngm3.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095014224001002/eh240467037_4-ngm3.xml","form_type":"4"}},{"id":1545433,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":1,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:05:48.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90442,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities were directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-001002","document":"eh240467037_4-ngm3.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095014224001002/eh240467037_4-ngm3.xml","form_type":"4"}},{"id":1545432,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":1,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:05:48.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2650177,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities were directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-001002","document":"eh240467037_4-ngm3.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095014224001002/eh240467037_4-ngm3.xml","form_type":"4"}},{"id":1545431,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":1,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:05:48.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":949862,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities were directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\"). (cont'd in FN 3)"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-001002","document":"eh240467037_4-ngm3.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095014224001002/eh240467037_4-ngm3.xml","form_type":"4"}},{"id":1643170,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-14T16:15:53.000Z","date":"2024-02-12","kind":"purchase","planned":false,"acquired":true,"shares":2222222,"price":4.5,"value":9999999.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(Continued from Footnote 1) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":13599275,"source":{"system":"sec-edgar","filing":"0000950170-24-015234","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000095017024015234/ownership.xml","form_type":"4"}},{"id":1736484,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92149,"kind":"person","name":"COLUMN GROUP L P","position":1,"cik":"0001347769","reported_name":"COLUMN GROUP L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":2,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-17T16:33:24.000Z","date":"2023-11-16","kind":"purchase","planned":false,"acquired":true,"shares":5840,"price":0.6211,"value":3627.224,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6198 to $0.6221, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":949862,"source":{"system":"sec-edgar","filing":"0000950170-23-064858","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095017023064858/ownership.xml","form_type":"4"}},{"id":1736483,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92149,"kind":"person","name":"COLUMN GROUP L P","position":1,"cik":"0001347769","reported_name":"COLUMN GROUP L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":2,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-17T16:33:24.000Z","date":"2023-11-15","kind":"purchase","planned":false,"acquired":true,"shares":16791,"price":0.7075,"value":11879.6325,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.681 to $0.7201, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":944022,"source":{"system":"sec-edgar","filing":"0000950170-23-064858","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095017023064858/ownership.xml","form_type":"4"}},{"id":1954184,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-14T16:12:07.000Z","date":"2023-03-10","kind":"purchase","acquired":true,"shares":6779,"price":2.5956,"value":17595.5724,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.58 to $2.60, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":11377053,"source":{"system":"sec-edgar","filing":"0000899243-23-008390","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000089924323008390/doc4.xml","form_type":"4"}},{"id":2022691,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-10T16:32:20.000Z","date":"2023-02-08","kind":"purchase","acquired":true,"shares":1500000,"price":2.6,"value":3900000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(Continued from Footnote 1) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":11370274,"source":{"system":"sec-edgar","filing":"0000899243-23-004584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000089924323004584/doc4.xml","form_type":"4"}},{"id":2038421,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92149,"kind":"person","name":"COLUMN GROUP L P","position":1,"cik":"0001347769","reported_name":"COLUMN GROUP L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":2,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-01T16:31:23.000Z","date":"2023-01-31","kind":"purchase","acquired":true,"shares":176730,"price":4.9986,"value":883402.578,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.995 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":927231,"source":{"system":"sec-edgar","filing":"0000899243-23-003132","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000089924323003132/doc4.xml","form_type":"4"}},{"id":2038420,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92149,"kind":"person","name":"COLUMN GROUP L P","position":1,"cik":"0001347769","reported_name":"COLUMN GROUP L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":2,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-01T16:31:23.000Z","date":"2023-01-30","kind":"purchase","acquired":true,"shares":7542,"price":4.9996,"value":37706.9832,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.99 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":750501,"source":{"system":"sec-edgar","filing":"0000899243-23-003132","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000089924323003132/doc4.xml","form_type":"4"}},{"id":2046350,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92149,"kind":"person","name":"COLUMN GROUP L P","position":1,"cik":"0001347769","reported_name":"COLUMN GROUP L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":2,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-25T16:38:20.000Z","date":"2023-01-23","kind":"purchase","acquired":true,"shares":9900,"price":4.9994,"value":49494.06,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.995 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":742959,"source":{"system":"sec-edgar","filing":"0000899243-23-002642","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000089924323002642/doc4.xml","form_type":"4"}},{"id":2048714,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-23T16:25:36.000Z","date":"2023-01-19","kind":"purchase","acquired":true,"shares":69739,"price":2.4979,"value":174201.04810000001,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.35 to $2.57, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":9870274,"source":{"system":"sec-edgar","filing":"0000899243-23-002382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000089924323002382/doc4.xml","form_type":"4"}},{"id":2048612,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92149,"kind":"person","name":"COLUMN GROUP L P","position":1,"cik":"0001347769","reported_name":"COLUMN GROUP L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":2,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-23T16:25:16.000Z","date":"2023-01-20","kind":"purchase","acquired":true,"shares":500,"price":4.996,"value":2498.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.98 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":733059,"source":{"system":"sec-edgar","filing":"0000899243-23-002381","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000089924323002381/doc4.xml","form_type":"4"}},{"id":2048611,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92149,"kind":"person","name":"COLUMN GROUP L P","position":1,"cik":"0001347769","reported_name":"COLUMN GROUP L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":2,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-23T16:25:16.000Z","date":"2023-01-19","kind":"purchase","acquired":true,"shares":37639,"price":4.9976,"value":188104.6664,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.975 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":732559,"source":{"system":"sec-edgar","filing":"0000899243-23-002381","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000089924323002381/doc4.xml","form_type":"4"}},{"id":2050858,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-19T16:18:04.000Z","date":"2023-01-18","kind":"purchase","acquired":true,"shares":135688,"price":2.5163,"value":341431.7144,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.37 to $2.60, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":9800535,"source":{"system":"sec-edgar","filing":"0000899243-23-002161","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000089924323002161/doc4.xml","form_type":"4"}},{"id":2050857,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":64486,"kind":"organization","name":"COLUMN GROUP III GP, LP","position":1,"cik":"0001790965","reported_name":"COLUMN GROUP III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64487,"kind":"organization","name":"COLUMN GROUP III, LP","position":2,"cik":"0001668159","reported_name":"COLUMN GROUP III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64488,"kind":"organization","name":"COLUMN GROUP III-A, LP","position":3,"cik":"0001668085","reported_name":"COLUMN GROUP III-A, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64489,"kind":"organization","name":"Column Group Opportunity III, LP","position":4,"cik":"0001931825","reported_name":"Column Group Opportunity III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64490,"kind":"organization","name":"Column Group Opportunity III GP, LP","position":5,"cik":"0001932874","reported_name":"Column Group Opportunity III GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":6,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-19T16:18:04.000Z","date":"2023-01-17","kind":"purchase","acquired":true,"shares":49463,"price":2.4947,"value":123395.3461,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.32 to $2.60, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":9664847,"source":{"system":"sec-edgar","filing":"0000899243-23-002161","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668085/000089924323002161/doc4.xml","form_type":"4"}},{"id":2053677,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":92149,"kind":"person","name":"COLUMN GROUP L P","position":1,"cik":"0001347769","reported_name":"COLUMN GROUP L P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64491,"kind":"organization","name":"TCG Opportunity III GP, LLC","position":2,"cik":"0001932445","reported_name":"TCG Opportunity III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-17T16:36:49.000Z","date":"2023-01-12","kind":"purchase","acquired":true,"shares":5378,"price":4.9466,"value":26602.8148,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.77 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":694920,"source":{"system":"sec-edgar","filing":"0000899243-23-001857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000089924323001857/doc4.xml","form_type":"4"}}],"next_cursor":"2023-01-17T16:36:49.000000Z,2053677"}